Cerus Co. (NASDAQ:CERS) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Cerus Co. (NASDAQ:CERS) have earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $8.00.

A number of equities analysts have weighed in on CERS shares. Stifel Nicolaus started coverage on shares of Cerus in a research report on Tuesday, August 27th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research upgraded shares of Cerus from a “sell” rating to a “hold” rating in a research report on Monday, October 7th. ValuEngine lowered shares of Cerus from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. BidaskClub lowered shares of Cerus from a “sell” rating to a “strong sell” rating in a research report on Friday, October 25th. Finally, Stephens started coverage on shares of Cerus in a research report on Thursday, August 22nd. They issued an “overweight” rating and a $8.00 price target for the company.

Shares of Cerus stock opened at $4.11 on Friday. Cerus has a 12-month low of $3.95 and a 12-month high of $6.88. The firm has a market cap of $607.59 million, a PE ratio of -9.34 and a beta of 1.60. The company has a quick ratio of 2.31, a current ratio of 2.77 and a debt-to-equity ratio of 0.95. The company’s fifty day simple moving average is $4.61 and its two-hundred day simple moving average is $5.16.

Cerus (NASDAQ:CERS) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01). Cerus had a negative net margin of 100.38% and a negative return on equity of 100.59%. The business had revenue of $18.00 million for the quarter, compared to analysts’ expectations of $17.69 million. During the same period in the prior year, the company posted ($0.11) earnings per share. The firm’s quarterly revenue was up 16.9% on a year-over-year basis. As a group, sell-side analysts expect that Cerus will post -0.5 earnings per share for the current fiscal year.

In related news, SVP Carol Moore sold 30,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $5.33, for a total transaction of $159,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Timothy B. Anderson sold 18,795 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $5.40, for a total transaction of $101,493.00. Following the transaction, the director now owns 177,649 shares of the company’s stock, valued at approximately $959,304.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 58,459 shares of company stock valued at $312,129. Company insiders own 7.26% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. boosted its position in shares of Cerus by 9.8% during the third quarter. Envestnet Asset Management Inc. now owns 27,477 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 2,455 shares during the last quarter. Raymond James Trust N.A. boosted its position in shares of Cerus by 13.6% during the third quarter. Raymond James Trust N.A. now owns 25,000 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 3,000 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Cerus by 8.5% during the third quarter. Janney Montgomery Scott LLC now owns 54,200 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 4,250 shares during the last quarter. Aperio Group LLC bought a new position in shares of Cerus during the second quarter worth $27,000. Finally, Prudential Financial Inc. boosted its position in shares of Cerus by 20.7% during the second quarter. Prudential Financial Inc. now owns 34,297 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 5,880 shares during the last quarter. Hedge funds and other institutional investors own 74.26% of the company’s stock.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Read More: How Do Mutual Funds Work?

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.